Pharmacy Podcast Network
Original podcast
Where to listenCopy share link
An update from NDPhA and PBM Reform initiatives.
5,256 words · 4 speakers
Thanks for listening to the Pharmacy Podcast Network.
Welcome to the PBM Reform Podcast, where we dive deep into the world of pharmaceutical benefit management, cutting through the noise to uncover the truth. Since 2019, we've been your go-to source for the latest on how PBMs impact patient care, drug pricing, and the very future of pharmacy. Here, we champion the role of pharmacists, the most knowledgeable advocates for medication safety and expertise. Join us as we expose and generate discussions that are reshaping healthcare and explore how we build a better payment system which focuses on advancing pharmacy care.
Welcome to the PBM Reform Podcast on the Pharmacy Podcast Network. This is Breck Rice. I'll be your host today, and I have the privilege of speaking with Michael Swab, who is the Executive Vice President with the North Dakota Pharmacists Association. Welcome, Mike.
Hey, Breck. How are you doing today?
Doing great, doing great. So, excited to hear more about what you've been involved in for your state, and then we'll get into some of your involvement with the national effort here too as well. We've seen some great progress being made in PBM reform. I think one of the biggest things that I've seen happen in the last few years is the gag clauses, getting the gag clauses removed out of pharmacy contracts. And so that's been super beneficial. To help the pharmacies be able to get medications at whatever the best cost is, right?
That they don't have to collect the co-pay if the cash price is is less for them. So that was exciting when that came about. You know, I've been working with community pharmacy for over 20 years now. I absolutely love the industry and want to do everything I can can to help. But there's still so much more that has to be done. So I wanted to get an update from you, Michael, on, you know, what is the association working on right now? For legislation or regulatory changes for PBMs in your state?
I appreciate that, Breck. And really, when it comes to PBM reform, I think it's clear that we've seen movement in pretty much all of the states at this point in time. And, you know, I'm sure there's a variety of reasons for that. Personally, I think sometimes because we have, you know, little happening in Congress. I think states feel that they need to take it upon themselves then and kind of what I would consider to be more of that grassroots push then from the states. And I think that's a lot of what we've seen. We've kind of seen that ground swelling at the state level and then which of course brings more attention to things federally. And I hope that we can get a few meaningful pieces of PBM reform passed in Congress.
As far as what we're concentrating on a lot of, and I think a lot of my colleagues around the country would agree is is PBM enforcement. You know, we've got a variety of reforms that we've put in place and other states have put in place. And, you know, really, I think PBM enforcement is going to be probably one of the biggest issues that all states probably are currently focused on or will be focused on. And I guess for me personally, you know, I took this job about 18 years ago and it didn't take long. I'd say, well, with in that first year or so, I was kind of like, what are PBMs? Who are these guys? You know, because they are kind of that hidden secret in healthcare.
But man, do they control so many aspects of healthcare and so many avenues of prescription drug supply chain that, you know, once you really started getting into it and you really looked at it and you really started getting into the weeds and the details, you're like, boy. This really is an issue that I that caught my attention, needs my attention, whether that affects me personally, professionally, or whatever the case might be. I think it's important for everybody to educate themselves a little bit more on what just is a PBM and how do they affect the supply chain and the cost of drugs. And so, again, PBM enforcement would comes to mind right away.
Okay. And so what are the biggest challenges for for implementing meaningful enforcement?
Well, I think right now, what we're finding out is that there's some states that have a variety of avenues that they've implemented to try to get enforcement, whether that's through the insurance department in their state, or whether that's, you know, looking at, okay, well, this law might have a penalty to it. And so hopefully they'll comply. At least here in North Dakota, we've got, we've got a number of PBM laws or provisions that we feel at least that the the PBMs are not adhering to. And so then the question comes down to, how do we get a, I guess, meaningful enforcement in place? You know, let's, let's face it, most of your insurance departments, you know, they don't have, you know, attorneys
that specialize in pharmacy. They don't have maybe economists that specialize in in the supply chain type of area. And so you really kind of end up with this, you know, even when insurance commissioners support PBM enforcement, they're not quite sure where to maybe start sometimes, or they need additional FTEs or, you know, need additional staff to help with some of those enforcement efforts. So right out of the gate, there's a huge learning curve. And then the other side of it is, is that, you know, you have a lot of states that maybe even would like to see their attorney general or bring even states want to maybe bring, maybe a pharmacy wants to bring an action against a PBM. But even
in those cases, I mean, most of your local state attorneys in the various pockets throughout the state, I mean, again, they don't typically know what a PBM is. They don't know How they operate, they don't have the expertise for you bring a PBM case to them and you know, you know, one of your local state attorney attorneys and they're probably starting at square one as well. So I just think there's just a lack of experts in that area. There's a, a, a lack of awareness and in, in, in how some of that has to operate in order to bring enforcement. So again, you know, before you can even say, hey, we need to push enforcement. It's boy, there's a lot of education that needs to still take place.
Yeah.
And so I think that's
I think that's what a lot of people struggle with.
Yeah, absolutely. And, and not to mention that, that most PBMs employ more attorneys than any state, you know, government has, right? So
Oh, I mean, you hit the nail on the head. I mean, especially coming from a rural, small state like North Dakota. I mean, some of these PBMs probably have more attorneys than we do in our whole state. And, you know, the other side of that is when, when a, when a PBM sees a piece of legislation passed. Now, I, I won't get anybody to, to verify or, you know, I can't quote the individual on this, but let's just say that a reliable conversation with an, an individual that is quite credible and reliable told me that a particular PBM, at least that he used to work for, literally puts a team of attorneys into a room, not to figure out how
to comply with the law that is recently passed in the state, but how do we figure a way around the law that was recently passed?
Yep.
So again, right out of the bat, you have problems with enforcement because they've got a whole team of people that are trying to figure out how do we maybe not even have to comply with the law to begin with?
Yeah, no, absolutely. Absolutely. It's a, a tragedy on, you know, the industry to have middlemen going in there, figuring out ways to circumvent laws that are being written specifically to help, you know, us move forward with reforms. So, you know, to change it more to a, a positive note here, can you discuss with us any recent successes that you've had in your, in your state or even just nationally? You're involved nationally as well?
Uh, yes, as far as in, you know, here in North Dakota, we've had some success in, you know, educating individuals. Our legislators are very familiar with PBMs. Uh, so I feel that our members and in general, uh, those that are looking for PBM reform have done a good job of, of educating our, our local legislators. We've seen our public officials get to not only more educated, but get more involved. Um, and we've also seen, um, like our largest plan in the state, our public employers retirement system, they become more educated in how PBMs operate. We've seen, uh, you know, the, the larger employer groups that are self-funded
or, you know, fall under ERISA, they become more educated. Um, you know, it's tough though, because the, the PBMs hold such big market share um, that there's not a lot you can do sometimes, um, in terms of that competitiveness that should take place in, in a market. And so I, I, I think we've, we've been doing a good job of educating all those various players. Um, from, from more of a enforced, direct enforcement perspective. We've had some luck with our Department of Human Services, um, as well as our governor's office pushing a few things. But again, um, we, we've passed a number of PBM reform laws over the years.
And I mean, one of the, two sets of laws we passed in 2017, we spent four years in the legal system, all the way through our district court to the A Circuit, to the Supreme Court, right back down to the A Circuit, right on the heels of the Arkansas Rutledge decision. Um, you know, so we were successful, but again, it took us four years. Yeah. And a, a large chunk of change. Um, and, and so it becomes difficult. I mean, even when you have pharmacies that would like to bring action, they know what's ahead, they know it's going to take years, they know it's going to take a lot of money. And I think even when you talk to some of the larger firms, um, in the country, um, from a contingency basis, let's be honest, it's got to be well worth their while
to take the risk of going up against the behemoths, uh, that the PBMs are.
Yeah, exactly. Yeah, that going back to that example of them having more attorneys on staff than the entire state has. And now what about an independently owned pharmacy? It's it's pretty rough for them if they know they're going to be absolutely, you know, penalized for for getting involved in in some capacity. You know, what about on the national level, Michael? What what big progress have you seen for a nation for our nation in PBM reform?
Well, I'm excited to to hear and to see that we have multiple PBM reform bills that are, you know, introduced and currently trying to work their way through the political process. And so I I think from that perspective, that's that's a good step forward. That's exciting to see. But we need to get something to the finish line. You know, we need to get something meaningful through to the finish line. And we've seen from a national perspective, we've seen more and more members of Congress start to really get educated themselves and take aim at the PBMs. And, you know, it's just not this isolated example or this isolated case anymore. It's pretty systemic. We're seeing this kind of across the board where we have to do something.
It's just what does that something end up looking like? You know, fingers and toes are crossed. That something meaningful does get passed out there in in DC. But, you know, right now, it's just good to see at least we've made progress from the educational perspective. But we're also making progress in getting various bills introduced that are trying to address that that that PBM reform piece that employers need, taxpayers need, patients need. And yes, of course, pharmacists as a profession, they need it as well.
Yeah, give some examples of what, you know, specific reform that's that's hopefully going through the the process to be passed. You know, how will that impact independent pharmacies?
Yeah, so I'll start with one that, you know, just maybe not so much impacting the independent pharmacies right away, but just getting rid of spread pricing in Medicaid. You know, and, you know, I mean, just, just to think that while it's not illegal, I mean, for me personally, it's pretty suspect, but just to get rid of the spread pricing where a pharmacist obviously is paid one price, but you bill Medicaid or you bill the employer a higher price. Obviously, that distorts the overall cost of the medications right out of the gate. And, and really, over the years, has been a, you know, lucrative model for the PBMs. And we see all kinds of variations of that.
And we see, you know, just when you're going after spread pricing, well, then they change the game a little bit, and how do you bottle that all up? I mean, that's really what I think everybody's trying to do. But ultimately, I think that that helps. The other part of that, for the benefit of, of the profession of pharmacy and more particular independent pharmacies is, is at least then you're, you have a transparent model. You know what you're going to be paid, you know what you, know what to expect, and you're not playing this, you know, blind going into it, not having any idea what you're actually going to get paid for, especially when it comes to, you know, like generic drugs, for example. When you sign a contract and 85, 90% of your business, you don't know what you're going to be paid on until you actually have the, the claim, you know, get adjudicated, and then it comes back to you. Then you know what you're going to be paid.
I mean, I don't know about you, Breck, but think about that in any other profession that says, 90% of what you're going to make, I'm not going to tell you what you're going to get paid until after the patient's, you know, in front of the counter, and you have to fill the drug. You know, and, and by the way, this is what you're going to get paid. Don't care if it's going to be a, you know, a plus or minus for you, but, you know, that's when you find out, I mean, come on, I mean, this, it's, it's, it's actually laughable nowadays.
Yeah, yeah. And you're expected to just accept it because that's just what you do, right? So if you're, if you're the pharmacy owner, you know, the, the spread pricing is even larger in programs like workers comp, which is what my background is in for, you know, over 20 years in third-party claims processing for workers comp claims. And that spread is much larger, you know, and, and they hide in the contracts, all of these, you know, other fees that they tack on, like, you know, bill reviewing and doing all these other things that they claim are services, but they're just literally tacking on $50, $60 extra per
transaction on every claim, but yet expecting the pharmacy to only, you know, accept a, you know, minus 65 minus 70% of AWP.
Well, you definitely see that, you definitely see that play off. And you know, I've been to a number of employer meetings while they're discussing benefit design. And, you know, the PBMs and carriers will come in and say, oh, we've done the best that we can at controlling costs, you know, pharmacy spend was up 12%. We're, we're doing a great job of aggressively negotiating with our network of pharmacies. And we're all standing around, or pharmacies standing around scratching their head. They're like, well, we got a contract rate reduction. And I did 3% more in volume for 2% less more in reimbursement, but yet pharmacy spends up 12%. Doesn't make sense, obviously. And you tell me where that money's going.
Yeah, exactly. Yeah. For those of you that are just joining us, you're listening to the PBM Reform Podcast on the Pharmacy Podcast Network. Our special guest today, Michael Schwab, the Executive Vice President with the North Dakota Pharmacists Association, and having a discussion about some of the reform for PBMs that has taken place to this, this point, and, and what can still be done. You know, one thing that would really benefit pharmacies, when we talk about the impact on independence pharmacies, you know, in, in particular, is the, you know, we need to see some legislation that unbundles these networks.
You've got big players out there that, you know, buy up these other smaller PBMs and then they roll them into their networks. And so if, you know, if the pharmacy wants access to, you know, maybe the, all of the health patients for a big health, you know, care company, then they're forced to take all of the other little networks that they don't really need, but it's kind of an all or nothing. They, they say, well, if you want the 65 million lives over here on the, on the health side, well, you've got to take all these other little networks and they just bundle them together. Is there any, been any discussion or talk about unbundling those networks,
allowing the pharmacies to choose which networks they want to belong in?
You know, in North Dakota, we actually do have a law where the PBM has to kind of tell you or inform you who participates in that network. And that would be an area of, of contention a little bit too, where we don't always get that information from the PBMs, even though it was upheld by the courts that, you know, we have a right as, as a business owner to some of that information. And really what it, what it settles on is, is how else are you supposed to make an informed contract decision if you don't have some of that information? I mean, I might be in a city where I only have maybe 10 patients. And so it's like, well, for the benefit of those 10 patients, my community, I'm going to sign this contract, even though this contract is probably a, a very bad contract.
But on the flip side, you might have it where, you know, where you're looking at that and you're like, man, this is a big book of business for me. I have a ton of individuals under this network plan. I really need to, to really consider, am I able to sign this contract or participate in this contract? And then of course, you can try negotiating with that PBM. We all know how that typically goes. It's usually a take it or leave it type of contract, you know, or, or you have no, no leverage to really change the, the contract terms and conditions.
Right, right. Are you hearing anything about patients and, and having trouble with access to medications? Because the, the contract rates are just so ridiculous that the, the pharmacy can't afford to fill the script?
We're seeing more and more of that with Medicare Part D. It's kind of two-pronged. I mean, obviously, we're seeing more and more preferred networks coming out where some of your independent pharmacies aren't even allowed the option to participate in that network. But we're also seeing access for Medicare Part D suffer from, you know, at least with a small rural state like this on the, you know, because of the fact that pharmacies, you know, are reluctant to sign some of those really bad contracts.
You know, so I would also probably add, I think pharmacies are getting to a point because of that, we're also seeing, I mean, coupled with that, excuse me, we're seeing a lot more of your mail order pushes, especially in the area of specialty pharmacy. We actually just yesterday got involved with the call and it actually was with a pharmacist, I guess I probably got to be a little hesitant there, but was with a pharmacy here and it's in a real rural underserved area and the patient needed a specialty medication which was available in that community right then and there.
The rejection notice came that it had to be filled at the PBM specialty mail order pharmacy. And so I think what we're really seeing when I, when I talk about access, at least right now, we're really seeing the specialty mail order side really pose problems for access in a lot of our communities, at least at this point in time we are.
Yeah, no, I've heard that before and it's, it's really sad, right? And, and they, they have, the PBM has this, this view into what's being adjudicated and they can say, no, we, we'll just block that, not approve it so that we can have it come through our own pharmacy and completely bypass the community pharmacy right there in the community that's serving that patient. It's really sad. Have you heard anything similar with Department of Labor with, with you being a? A lot of rural pharmacies in in your association. The postal workers, right? They're all out in rural parts delivering the mail.
Are any of them having any access issues to getting their medications? Because what's the new rate minus eighty eight or something like that on the Department of Labor?
Well, I know there's a number of federal plans out there. Where unfortunately, you know, they've they've moved to some of that preferred or mandated type of arrangements. And yes, it does have an effect on not only patient choice, patient access. But I I guess I would also question just the overall cost. When you allow one entity to basically control so many aspects of your health benefit, which includes, you know, exclusive
mail order. How do you really truly know you're getting a fair deal other than what that individual tells you? Because there's no nobody else to really can to compete with or to help drive that price. And if you look at the specialty mail order market, I believe the three big PBMs right now pretty much control most of the specialty mail order market. You know, really, when you look at PBMs in general and the vertical integration that we've seen with healthcare. Obviously, it's all done under the guise of we're going to save money. I I just have never seen that play out to where, you know, it's we're going to save you money, but just don't ever ask us to show you how. But in the meantime, our three largest health insurance
companies that are all vertically integrated, all in the business of pharmacy, all get to set their direct competitors in terms, conditions, reimbursement rates, have access to that patient information on a daily basis, etc. You know, they they all have the ability to, you know, I I guess lack, I'm trying to think of the words to to really drive out some of that competition. And we've seen some of that. Uh, they have all the information. I mean, look, if if you're, if you're Wells Fargo, Breck, and you get to determine all of your terms and conditions and your reimbursement rates for all your competing banks, and you get to see all their customer information on a daily basis, it's a pretty damn sweet deal for you, isn't it?
Yeah, yeah.
And there would be, and and there'd be all anarchy breaking loose out in DC if that was the case. But for pharmacy, apparently, it's okay.
Yeah, no, I I you have so much money being driven through those those programs that they can afford, you know, lots of lobbying, lots of special interest groups to really push forward their their agenda. I mean, it's like, what was it? Not not even a year and a half, two years ago that they had the first, um, uh, hearing, FTC hearing and, um, and it was, you know, it was a hung jury. I mean, they just, no one really listened to the pharmacy side on that, even though there were over 200 pharmacies there that were, you know, that were bringing forth, uh, uh, different information and examples and of how they'd,
you know, been wrongly dealt with. But yet, you know, it was already decided that, oh, no, we're we're not gonna, we're not gonna pursue this any, you know, any longer. And luckily, the chairman at the FTC saw that it was a hung jury and and put a new committee together to go back through the process again. But yeah, that was just ridiculous that first time around.
Were you a part of that?
Can you hear me, Breck? I'm having a hard time hearing you all of a sudden. My apologies.
No, I I hopefully it sounds okay here. But yeah, I can hear you, uh, just fine.
Okay, excellent. Sorry, I missed that last part.
No, just wondering if if you were a part of that first go around with the, um, with the FTC, uh, you know, reviewing, um, you know, uh, the, you know, the the PBMs and and some of their unscrupulous, uh, practices.
You know, we did have some conversations. I do know that they reached out with a few requests from some of our members as well, but I believe they were doing that around the country. And I've said for a long time, whether that's the DOJ, whether that's the FTC, or whether that's Congress, you know, somebody really needs to start looking under the microscope or pull back the curtain in The Wizard of Oz, per se, to really get at what are some of the things going on behind the scenes. Again, going back to my last comment, I mean, all three of those big insurance companies who are all vertically and horizontally
integrated, you know, they're all, all three now basically on the top 10 or 15 of Forbes 500. And yes, profit isn't a swear word, but when it comes to the basic needs of our citizens of this country, you know, things do have to be reformed. And I think that's why we're seeing what we're seeing take place. I think that's why my patients are fed up. I think that's why the profession of pharmacy is fed up. You know, and I think legislators in our respective states and Congress is finally saying enough's enough. We need to figure out how to do this.
Yeah, absolutely. So, Michael, have you seen any changes for the communications that are being sent out to patients? Because when a patient is going to receive like a maintenance drug, so maybe they're going to need a monthly refill on this medication, is there anything that the state is looking at to keep the PBM from sending out letters making it look like that the only option is for that patient to get their refills through mail order and bypass your members?
It's funny you bring that up. I shouldn't say it's not literally funny, but it happens all the time, happens across this country. And when you do approach, whether that's CMS, Centers for Medicaid and Medicare, or your local insurance department, or even the PBM, you know, they say, you know, it's an oversight, that's our fault, sorry about that, but they won't issue a retraction letter. And by then, you've already seen some of that volume shift, or some of those patients, you know, feel like, oh, they're not in network, or, oh, I can't get this here now. And so they've already migrated, or that volume shift has already kind of taken place. But again, in the years I've been doing this, I've never once seen a retraction letter by the PBM basically stating, hey, sorry, this was our
mistake. You know, you can still go back to your local pharmacy, you know, that was a, you know, an oversight, or however they want to state it. I mean, they're gonna, you know, doll it up. But, you know, we haven't seen that take place. But yeah, we definitely see the letters go out.
Yeah, yeah, I'm wondering if there isn't some, you know, bill that could be passed, you know, an anti-poaching bill, or something like that. Because those letters are worded strongly. I received one personally for myself. I was on a medication that I was going to get multiple refills, and I got the PBM letter, and it's worded very strongly, like, that was my only option, was to get it through their mail order fulfillment.
Well, not only is it worded strongly to maybe have you perceive that's your only option, the other little twist to that is, is oftentimes, those letters come with, hey, come to us, and we'll waive your copays on a 90-day supply. But yet, by contract, the PBMs and carriers won't allow the pharmacies to waive that same maintenance med and waive that copay. Obviously, that's done by design, and for a reason.
Yeah, absolutely. Well, Mike, it's been a pleasure visiting with you today. Is there any specific item that we didn't cover that you think would be important for our listeners to hear?
You know, I could keep talking on and on for quite some time on PBM issues. I just think it's important for those that aren't familiar with PBMs to really try to educate themselves the best they can. I think it's extremely important for them to talk to their local pharmacist, to ask questions, and find out additional details. And I really hope that not only do our states continue the PBM reform efforts, but I hope that patients and employers and the taxpayers ultimately paying for a lot of this, start helping push those issues forward as well. And last but not least, I hope in Congress, we finally can get at least something meaningful in the form of PBM reform.
I don't think it'll ever go far enough, at least not for me, but we'll take a baby step when we can get it.
Yeah, just keep chipping away, Adam. Well, thank you, Michael Suave, the Executive Vice President at the North Dakota Pharmacist Association. He's been our guest today here on the PBM Reform Podcast on the Pharmacy Podcast Network. Thanks for being here with us today and have a great rest of your week.
Page updated November 15, 2026 · transcript and summary are machine-generated